Update shared on27 Aug 2025
Fair value Increased 1.80%Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged.
What's in the News
- Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.
- The partnership leverages Spear Bio's SPEAR platform, offering sensitivity far exceeding current immunoassay technologies, and expands Bio-Techne's reach in neurodegeneration, inflammation, and oncology research markets.
- Bio-Techne's Simple Western™ technology was instrumental in the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, by enabling sensitive, reproducible quantification of complex protein biomarkers.
- A new distribution agreement with the U.S. Pharmacopeia allows Bio-Techne to sell USP monoclonal antibody and AAV reference standards alongside its analytical instruments, supporting global development and quality control of monoclonal antibody and gene therapy products.
- Integration of USP reference standards with Bio-Techne's systems, such as MauriceFlex™, enhances analytical accuracy and regulatory compliance for manufacturers, addressing key challenges in complex biologics development and commercialization.
Valuation Changes
Summary of Valuation Changes for Bio-Techne
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $64.15 to $65.31.
- The Future P/E for Bio-Techne remained effectively unchanged, moving only marginally from 45.86x to 46.68x.
- The Consensus Revenue Growth forecasts for Bio-Techne remained effectively unchanged, moving only marginally from 6.6% per annum to 6.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.